The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (MTOR) pathway is crucial for cellular functions and frequently hyperactivated in various cancers.
• Targeting this pathway represents a significant anti-cancer therapeutic strategy, leading to the development and FDA approval of multiple inhibitors.

Purpose of the Study:

• To review therapeutic targets within the PI3K/AKT/MTOR signaling pathway in solid tumors.
• To summarize the current clinical applications of PI3K, AKT, and MTOR inhibitors for cancers with specific mutations.
• To highlight novel inhibitors progressing through clinical trials.

Main Methods:

• Literature review of preclinical and clinical investigations.
• Analysis of therapeutic strategies targeting PI3K/AKT/MTOR signaling.
• Examination of FDA-approved inhibitors and emerging drug candidates.

Main Results:

• PI3K/AKT/MTOR pathway hyperactivation is a hallmark of many malignancies.
• Several PI3K, AKT, and MTOR inhibitors are approved for treating cancers with activating mutations (e.g., PIK3CA, AKT1/2, MTOR).
• New inhibitors targeting this pathway are advancing into clinical trials.

Conclusions:

• Targeting the PI3K/AKT/MTOR pathway is a validated anti-cancer approach for solid tumors.
• Ongoing research and development of novel inhibitors promise expanded therapeutic options for patients with PI3K/AKT/MTOR-driven cancers.
• Personalized medicine approaches focusing on specific pathway mutations are key to effective treatment.